NCT07180771View on ClinicalTrials.gov

A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Peripheral T Cell Lymphoma
Interventions
DRUG

BR101801

Patients will receive 200mg capsules (100mg+100mg)

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY

NCT07180771 - A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. | Biotech Hunter | Biotech Hunter